Patrick Tran1,2, Helen Maddock3, Prithwish Banerjee4,3. 1. Department of Cardiology, University Hospitals Coventry & Warwickshire, Coventry, CV2 2DX, UK. Patrick.tran2@uhcw.nhs.uk. 2. Centre for Sport, Exercise & Life Sciences, Faculty of Health and Life Sciences, Alison Gingell Building, Coventry University, Coventry, CV1 2DS, UK. Patrick.tran2@uhcw.nhs.uk. 3. Centre for Sport, Exercise & Life Sciences, Faculty of Health and Life Sciences, Alison Gingell Building, Coventry University, Coventry, CV1 2DS, UK. 4. Department of Cardiology, University Hospitals Coventry & Warwickshire, Coventry, CV2 2DX, UK.
Abstract
PURPOSE OF REVIEW: This review combines existing mechano-energetic principles to provide a refreshing perspective in heart failure (HF) and examine if the phenomenon of myocardial fatigue can be rigorously tested in vitro with current technological advances as a bridge between pre-clinical science and clinical practice. RECENT FINDINGS: As a testament to the changing paradigm of HF pathophysiology, there has been a shift of focus from structural to functional causes, as reflected in its modern universal definition and redefined classification. Bolstered by recent landmark trials of sodium-glucose cotransport-2 inhibitors across the HF spectrum, there is a rekindled interest to revisit the basic physiological tenets of energetic efficiency, metabolic flexibility, and mechanical load on myocardial performance. Indeed, these principles are well established in the study of skeletal muscle fatigue. Since both striated muscles share similar sarcomeric building blocks, is it possible that myocardial fatigue can occur in the face of sustained adverse supra-physiological load as a functional cause of HF? Myocardial fatigue is a mechano-energetic concept that offers a novel functional mechanism in HF. It is supported by current studies on exercise-induced cardiac fatigue and reverse translational science such as from recent landmark trials on sodium glucose co-transporter 2 inhibitors in HF. We propose a novel framework of myocardial fatigue, injury, and damage that aligns with the contemporary notion of HF as a continuous spectrum, helps determine the chance and trajectory of myocardial recovery, and aims to unify the plethora of cellular and molecular mechanisms in HF.
PURPOSE OF REVIEW: This review combines existing mechano-energetic principles to provide a refreshing perspective in heart failure (HF) and examine if the phenomenon of myocardial fatigue can be rigorously tested in vitro with current technological advances as a bridge between pre-clinical science and clinical practice. RECENT FINDINGS: As a testament to the changing paradigm of HF pathophysiology, there has been a shift of focus from structural to functional causes, as reflected in its modern universal definition and redefined classification. Bolstered by recent landmark trials of sodium-glucose cotransport-2 inhibitors across the HF spectrum, there is a rekindled interest to revisit the basic physiological tenets of energetic efficiency, metabolic flexibility, and mechanical load on myocardial performance. Indeed, these principles are well established in the study of skeletal muscle fatigue. Since both striated muscles share similar sarcomeric building blocks, is it possible that myocardial fatigue can occur in the face of sustained adverse supra-physiological load as a functional cause of HF? Myocardial fatigue is a mechano-energetic concept that offers a novel functional mechanism in HF. It is supported by current studies on exercise-induced cardiac fatigue and reverse translational science such as from recent landmark trials on sodium glucose co-transporter 2 inhibitors in HF. We propose a novel framework of myocardial fatigue, injury, and damage that aligns with the contemporary notion of HF as a continuous spectrum, helps determine the chance and trajectory of myocardial recovery, and aims to unify the plethora of cellular and molecular mechanisms in HF.
Authors: P J O'Brien; H Shen; J Weiler; C D Ianuzzo; C Wittnich; G W Moe; P W Armstrong Journal: Can J Physiol Pharmacol Date: 1991-02 Impact factor: 2.273
Authors: Jens Sörensen; Hendrik Johannes Harms; John M Aalen; Tomasz Baron; Otto Armin Smiseth; Frank A Flachskampf Journal: JACC Cardiovasc Imaging Date: 2019-12-18
Authors: Ignatios Ikonomidis; Victor Aboyans; Jacque Blacher; Marianne Brodmann; Dirk L Brutsaert; Julio A Chirinos; Marco De Carlo; Victoria Delgado; Patrizio Lancellotti; John Lekakis; Dania Mohty; Petros Nihoyannopoulos; John Parissis; Damiano Rizzoni; Frank Ruschitzka; Petar Seferovic; Eugenio Stabile; Dimitrios Tousoulis; Dragos Vinereanu; Charalambos Vlachopoulos; Dimitrios Vlastos; Panagiotis Xaplanteris; Reuven Zimlichman; Marco Metra Journal: Eur J Heart Fail Date: 2019-03-12 Impact factor: 17.349
Authors: Tariq Ahmad; P Elliott Miller; Megan McCullough; Nihar R Desai; Ralph Riello; Mitchell Psotka; Michael Böhm; Larry A Allen; John R Teerlink; Giuseppe M C Rosano; Joann Lindenfeld Journal: Eur J Heart Fail Date: 2019-08-13 Impact factor: 15.534
Authors: Daniele Masarone; Michelle M Kittleson; Stefano De Vivo; Antonio D'Onofrio; Ernesto Ammendola; Gerardo Nigro; Carla Contaldi; Maria L Martucci; Vittoria Errigo; Giuseppe Pacileo Journal: J Clin Med Date: 2022-10-04 Impact factor: 4.964